RE:RE:RE:RE:RE:RE:RE:RE:RE:RBCFor me a yes/no answer to one very simple question would seriously reduce the uncertainty about the clinical significance of the results. Has Grinspoon shared any of the 12 month data results or conclusions with the company? In essence we dont need to know any numbers just whether the company has had eyeballs on them.
A "yes" would suggest the introduction of NASH into the discussion is based on something tangible. It would explain the timing of the addition to the investor presentation and the resources spent putting a plan together.
jfm1330 wrote: From what I can see NASH is out of all the projections from analysts. As I said yesterday, my optimism is up a notch on that front after what Marsolais said yesterday. They seem well prepared with a plan to execute on NASH, based on how good the results will be. After reading and analyzing the results from the previous study from Grinspoon yesterday, I am now convinced that with a trial specefically on NASH patients, the results are going to be positive. The only question is how positive will they be and if they will be clinically significative enough to justify some king of regulatory and commercial actions. There is no endpoints numbers to meet in the study, so it is hard to evaluate what they need to achieve to convince the FDA.